kuraray


News Releases 2007

Revision of plan for integration of medical device businesses

July 10, 2007
Kuraray Co., Ltd.
Kuraray Medical Inc.
Asahi Kasei Pharma Corp.
Asahi Kasei Medical Co., Ltd.

Kuraray Medical (KM), wholly owned subsidiary of Kuraray, and Asahi Kasei Medical (AM), wholly owned subsidiary of Asahi Kasei Pharma, have revised their plan for the integration of medical device businesses as announced on December 14, 2006.

Businesses subject to integration on October 1, 2007

As previously announced Dialyzers and therapeutic apheresis devices of AM and KM.
As revised Dialyzers and therapeutic apheresis devices of AM and dialyzers of KM.

Proportion of ownership of the integrated company

As previously announced 85% by Asahi Kasei Pharma, 15% by Kuraray Medical
As revised 93% by Asahi Kasei Pharma, 7% by Kuraray Medical

Reason for revision

In the course of prior consultation with the Japan Fair Trade Commission (JFTC), it became apparent that a response from the JFTC to the effect that there would be no concern of restraint on competition in the domestic market for therapeutic apheresis devices would not be forthcoming soon enough to enable the planned business integration to proceed on schedule. AM and KM therefore opted to proceed first with an integration only of their dialyzer businesses. The revision of the proportion of ownership of the integrated company reflects valuation based on the revised scope of businesses subject to integration.

Outlook

AM produces devices based on polysulfone hollow-fiber membrane technology, the global standard for high-performance clearance of low-molecular-weight proteins, and devices based on cellulose hollow-fiber technology, while KM produces devices based on Eval® ethylene-vinyl alcohol copolymer (EVOH) hollow-fiber technology, featuring outstanding biocompatibility and enabling mild and gentle therapy for older patients and those just beginning treatment. The integration of the two companies’ hollow-fiber technology and know-how will accelerate the development of next-generation devices which offer greater safety and efficacy, enabling the integrated operation to enjoy a solid position as a global leader in medical devices, well placed for expansion and growth.

Integration process

The Sepacell™ leukocyte reduction filter and Planova™ virus removal filter businesses of AM will be transferred to a newly established company. AM, retaining its dialyzer and therapeutic apheresis device businesses, will be renamed Asahi Kasei Kuraray Medical Co., Ltd. The dialyzer businesses of KM will be transferred to Asahi Kasei Kuraray Medical. KM will retain its dental adhesive and filling resin business and its therapeutic apheresis device business. A-K Membrane Manufacturing Co., Ltd., joint venture of AM and KM for the production of Eval® hollow-fiber membrane for medical devices, will become a wholly owned subsidiary of Asahi Kasei Kuraray Medical, and then merged with that company.

Schematic representation of the business integration
(percentages indicate ownership)

Profile of the integrated business

Company name Asahi Kasei Kuraray Medical Co., Ltd.
President To be named from Asahi Kasei Medical
Scheduled start of operation October 1, 2007
Paid-in capital ¥800 million (tentative)
Shareholding 93% by Asahi Kasei Pharma, 7% by Kuraray Medical
Head office Tokyo, Japan
Business line Development, production, and sale of dialyzers and therapeutic apheresis products
Production sites Nobeoka, Miyazaki, Japan; Oita, Japan; Hangzhou, Zhejiang, China
Sales offices Japan, US, EU, China, Korea
Employees Approx. 1,400
FY 2007 sales forecast ¥40 billion (annualized)
FY 2010 sales forecast ¥48 billion

Kuraray Medical corporate profile

President Hideo Horii
Establishment June 2001
Paid-in capital ¥2.5 billion
Shareholding 100% by Kuraray Co., Ltd.
Head office Tokyo, Japan
Main products Dialyzers, therapeutic apheresis products, dental adhesive and filling resin
Production facilities Kurashiki - production of hollow-fiber dialyzer membrane, dental adhesive, and dental filling resin
Employees Approx. 300 (as of Mar. 31, 2007)
Sales ¥11.8 billion (year ended March 2007)

Asahi Kasei Medical corporate profile

President Yasuyuki Yoshida
Establishment July 1974
Paid-in capital ¥800 million
Shareholding 100% by Asahi Kasei Pharma
Head office Tokyo, Japan
Main products Dialyzers, therapeutic apheresis products, leukoreduction filters for transfusion, virus removal filters
Production facilities Nobeoka - production of hollow-fiber dialyzer membrane and other products
Oita - assembly of dialyzers and blood filters
China - assembly of dialyzers
Employees Approx. 1,700 (as of Mar. 31, 2007)
Sales ¥43.1 billion (year ended March 2007)